At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 102 enrolled
Drug / intervention
lamictaldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Evaluation of BW430C in Epilepsy<Phase III Study>
In Brief
A Phase 3 clinical trial evaluating lamictal for Epilepsy. Completed, enrolled 102 participants across 2 sites.
Detailed Summary
To evaluate safety information of BW430C when administered using the lower starting doses and slower dose escalations as recommended Global Data Sheet
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
Countries, Japan
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedNov 2006
Primary CompletionMar 2009
Study CompletionMar 2009
TodayJul 2026
First PostedNov 3, 2006
Enrollment StartAug 7, 2006
Primary CompletionMar 1, 2009
Study CompletionMar 26, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.7 years ago
Interventions
lamictaldrug
anti-epileptic drug